Adagio Therapeutics Profit Margin

The latest profit margin for ADGI is -183.9% as of June 2026. That compares with 82.13% in the prior-year period — down 323.9% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Adagio Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADGI's profit margin moved from 82.13% to -183.9% — a 323.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adagio Therapeutics's valuation or profitability profile.

Against Healthcare companies, ADGI currently prints -183.9% for profit margin, while the sector average sits near 9.48%. That is roughly 2039.7% below the sector mean. Large gaps often invite a closer look at Adagio Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Adagio Therapeutics converts resources into returns. At -183.9%, ADGI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 82.13% in the prior-year period — down 323.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADGI's profit margin (-183.9%), review year-over-year change from 82.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.